CELC · Celcuity Inc
Price
Snapshot
50 fields · last close| Market Cap | $4.72B |
| P/E | — |
| Float | 40.66M |
| Beta | 0.12 |
| Volatility | 5.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Mid cap |
| Macro sensitivity | Low |
| Clavix score | 56 |
| Price | 95.28 |
| Change | −1.19% |
| Prev Close | 96.43 |
| Open | 97.11 |
| Day Low | 94.92 |
| Day High | 98.00 |
| Avg Vol | 1 |
| Avg $ Vol | $72.76M |
| 52W High | 151.02 |
| 52W Low | 44.42 |
| 52W Pos | 47.7% |
| From High | −36.91% |
| From Low | +114.50% |
| Max DD 1Y | −43.25% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +3.61% |
| SMA 50 | +0.91% |
| SMA 200 | −10.23% |
| RSI (14) | 55.9 |
| Vol 30D | 52.4% |
| Vol 90D | 84.3% |
| 1Y Range | 44–151 |
| Daily bars | 506 |
| Perf Week | +3.42% |
| Perf Month | +3.78% |
| Perf Quarter | +4.28% |
| Perf Half Y | −16.32% |
| Perf Year | +77.92% |
| Perf YTD | −5.24% |
| Prev Day | −1.19% |
| Clavix | C- |
| Debt / Eq | 3.20 |
| Curr Ratio | 10.55 |
| Int Cover | -34.8× |
| FCF Margin | — |
| Rev Growth | — |
| Profit | Mixed |
| Leverage | Very High |
| Sector rank | 26 / 35 |
Clavix risk grade
regraded every trading dayCELC grades C-, 56 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (32, weak). 2 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 26 of 35 in Biotechnology by Clavix score.
How rough the ride is
| CELC | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.12 | 0.50 |
| Volatilityannualized | 5.0% | 13.2% |
| Max drawdown, past yearworst peak-to-trough fall | −43.3% | — |
| Typical daily movemedian absolute daily change | 2.28% | — |
| Days beyond ±3%of the last 252 sessions | 9337% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| CELC | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.12 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| CELC | |
|---|---|
| 1 week | +3.4% |
| 1 month | +3.8% |
| Year to date | −5.2% |
| 1 year | +77.9% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| CELC | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 14 Jul |
| Average score0 most bearish, 100 most bullish | 64 |
| Bullish · bearisharticles above 60 · below 40 | 20 · 6 |
| Directionarticles whose tone is improving vs worsening | 20 ↑ 6 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| CELC | |
|---|---|
| Revenue growthyear over year | — |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Biotechnology
36 companies| Metric | CELC | Sector spread | Median |
|---|---|---|---|
| Beta | 0.12 | 0.50 | |
| Volatility | 5.0% | 13.2% | |
| Debt / equity | 3.20 | 0.24 | |
| Current ratio | 10.55 | 3.73 | |
| Interest coverage | -34.8× | -0.2× |
Recent news
most recent scored articles · the chip is the article’s score · click to openCelcuity's breast cancer drug Revtopik received FDA approval on July 14, and on August 13 the company held a conference call outlining plans to begin commercial sales. The article frames the launch as costly, though the body text is truncated and full financial details were not provided.
Artia Global Partners LP opened a new position in Celcuity (CELC) during the second quarter, buying 59,316 shares, according to its SEC 13F filing (a quarterly disclosure of institutional holdings).
Celcuity has asked the FDA to approve its drug REVTORPYK (gedatolisib) for a specific group of breast cancer patients: those with HR+/HER2- disease that carries a PIK3CA gene mutation and has spread or returned after at least one round of hormone therapy. The request, called a supplemental New Drug Application (sNDA), was submitted on August 26, 2026.
Celcuity submitted an application to the FDA (called a supplemental New Drug Application, or sNDA) asking to expand approval of its drug REVTORPYK (gedatolisib) to treat a specific group of breast cancer patients: those whose tumors are hormone receptor positive, HER2 negative, and carry a PIK3CA genetic mutation, and whose disease has worsened after at least one hormone-based treatment.
On August 26, 2026, Celcuity filed a supplemental New Drug Application with the FDA for its drug REVTORPYK (generic name gedatolisib). The application seeks approval to treat HR-positive, HER2-negative advanced or metastatic breast cancer patients whose tumors carry a PIK3CA gene mutation, after their disease worsened following at least one round of hormone-blocking therapy.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| IOVA | Iovance Biotherapeutics Inc | D- | $3.94B | — | 0.90 | Compare |
| ERAS | Erasca Inc | D | $5.69B | — | 0.70 | Compare |
| PTCT | PTC Therapeutics Inc | B- | $5.96B | 8.78 | 0.49 | Compare |
| CGON | CG Oncology Inc | B- | $6.59B | — | 0.21 | Compare |
| CAI | Caris Life Sciences Inc | C | $7.16B | 59.62 | 0.42 | Compare |
| TWST | Twist Bioscience Corp | D+ | $8.47B | — | 2.26 | Compare |
| TGTX | TG Therapeutics Inc | B- | $8.68B | 19.73 | 1.90 | Compare |
| SYRE | Spyre Therapeutics Inc | — | $8.87B | — | 2.95 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.